EGFR and lung adenocarcinoma: Lung adenocarcinomas with activating mutations in the epidermal growth factor receptor (EGFR) gene represent the most common subset of targetable driver-positive non-small cell lung cancers (NSCLCs) and comprise ~10–15% of Caucasian patients and ~40–50% of East-Asian advanced NSCLC patients.